Temporal trends in mortality among people who use drugs compared with the general Dutch population differ by hepatitis C virus and HIV infection status

AIDS

Volumn 28, Issue 17, 2014, Pages 2589-2599

  Van Santen, Daniëla K ^a   Van Der Helm, Jannie J ^a   Grady, Bart P X ^a,c   De Vos, Anneke S ^b   Kretzschmar, Mirjam E E ^b,d   Stolte, Ineke G ^a,c   Prins, Maria ^a,c  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Causes of death; Hepatitis C; HIV; People who use drugs; Standardized mortality ratio; Trends

Indexed keywords

ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STANDARDIZED MORTALITY RATIO; ADDICTION; CHRONIC HEPATITIS C; COMPLICATION; EPIDEMIOLOGY; MORTALITY; NETHERLANDS; PROSPECTIVE STUDY; SURVIVAL; YOUNG ADULT;

ADULT; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NETHERLANDS; PROSPECTIVE STUDIES; SUBSTANCE-RELATED DISORDERS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84927794620     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000450     Document Type: Article

References (35)

1. Buster M. Centrale Methadon Registratie Jaarverslag 1993. Amsterdam: GG> 1994.
2. Van Brussel GH. Methadone treatment by general practitioners in Amsterdam. Bull N Y Acad Med 1995; 72: 348-358.
3. van den Berg CH. Smit C. Bakker M. Geskus RB. Berkhout B. Jurriaans S. et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007; 22: 183-193.
4. Matser A. Urbanus A. Geskus R. Kretzschmar M. Xiridou M. Buster M. et al. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012; 107: 614-623.
5. Buning EC. Coutinho RA. Van Brussel GH. van Santen GW. van Zadelhoff AW. Preventing AIDS in drug addicts in Amsterdam. Lancet 1986; 1: 1435.
6. Van Haastrecht HJ. Van den Hoek JA. Bardoux C. Leentvaar-Kuypers A. Coutinho RA. The course of the HIV epidemic among intravenous drug users in Amsterdam. The Netherlands. Am J Public Health 1991; 81: 59-62.
7. Buning EC. Van Brussel GH. Van Santen G. The 'methadone by bus' project in Amsterdam. Br J Addict 1990; 85: 1247-1250.
8. Van den Hoek JA. Van Haastrecht HJ. Coutinho RA. Risk reduction among intravenous drug users in Amsterdam under the influence of AIDS. Am J Public Health 1989; 79: 1355-1357.
9. van den Berg C. Smit C. Van Brussel G. van den Berg C. Smit C. Van Brussel G. et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462.
10. Bhaskaran K. Hamouda O. Sannes M. Boufassa F. Johnson AM. Lambert PC. Porter K. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300: 51-59.
11. Lewden C. Bouteloup V. De Wit S. Sabin C. Mocroft A. Wasmuth JC. et al. All-cause mortality in treated HIV-infected adults with CD4>/U500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41: 433-445.
12. van der Helm J. Geskus R. Sabin C. Meyer L. Del Amo J. Chene G. et al. Effect of HCV infection on cause-specific mortality after HIV seroconversionbefore and after 1997. Gastroenterology 2012; 144: 751-760e2.
13. Smit C. Lindenburg K. Geskus RB. Brinkman K. Coutinho RA. Prins M. Highly active antiretroviral therapy (HAART) among HIV-infected drug users: a prospective cohort study of sexual risk and injecting behaviour. Addiction 2006; 101: 433-440.
14. Mehta SH. Kirk GD. Astemborski J. Galai N. Celentano DD. Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore. Maryland. 1996-2008. Clin Infect Dis 2010; 50: 1664-1671.
15. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000; 1: 224-231.
16. van Asten LC. Boufassa F. Schiffer V. Brettle RP. Robertson JR. Hernandez Aguado I. et al. Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health 2003; 13: 347-349.
17. Lindenburg CE. Lambers FA. Urbanus AT. Schinkel J. Jansen PL. Krol A. et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
18. Grebely J. Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-339.
19. Bargagli AM. Hickman M. Davoli M. Perucci CA. Schifano P. Buster M. et al. Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health 2006; 16: 198-202.
20. Mathers BM. Degenhardt L. Bucello C. Lemon J. Wiessing L. Hickman M. Mortality among people who inject drugs: a systematic review and meta-analysis. Bull World Health Organ 2013; 91: 102-123.
21. Aldaz P. Moreno-Iribas C. Egues N. Irisarri F. Floristan Y. Sola-Boneta J. et al. Mortality by causes in HIV-infected adults: comparison with the general population. BMC Public Health 2011; 11: 300-308.
22. Hernando V. Perez-Cachafeiro S. Lewden C. Gonzalez J. Segura F. Oteo JA. et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: Differences by HCV co-infection. J Hepatol 2012; 57: 743-751.
23. Jimenez-Trevino L. Saiz PA. Garcia-Portilla MP. Diaz-Mesa EM. Sanchez-Lasheras F. Buron P. et al. A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav 2011; 36: 1184-1190.
24. Evans JL. Tsui JI. Hahn JA. Davidson PJ. LumPJ. Page K.Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFOstudy.AmJ Epidemiol 2012; 175: 302-308.
25. Van den Hoek JA. Coutinho RA. Van Haastrecht HJ. van Zadelhoff AW. Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. AIDS 1988; 2: 55-60.
26. Gjersing L. Bretteville-Jensen AL. Gender differences inmortality and risk factors in a 13-year cohort study of street-recruited injecting drug users. BMC Public Health 2014; 14: 440-451.
27. SmitC. GeskusR. Walker S. SabinC. CoutinhoR. Porter K. PrinsM. Effective therapy has altered the spectrumof cause-specificmortality following HIV seroconversion. AIDS 2006; 20: 741-749.
28. Vicente J. Giraudon I. Matias J. Hedrich D. Wiessing L. Rebound of overdose mortality in the European Union 2003-2005: findings from the 2008 EMCDDA Annual Report. Euro Surveill 2009; 14: 1-2.
29. van Ameijden EJ. Coutinho RA. Large decline in injecting drug use in Amsterdam. 1986-1998: explanatory mechanisms and determinants of injecting transitions. J Epidemiol Community Health 2001; 55: 356-363.
30. van der Knaap N. Grady BP. Schim van der Loeff MF. Heijman T. Speksnijder A. Geskus R. Prins M. Drug users in Amsterdam: are they still at risk for HIV? PLoS One 2013; 8: e59125.
31. de Vos AS. van der Helm JJ. Matser A. Prins M. Kretzschmar ME. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? Addiction 2013; 108: 1070-1081.
32. Greub G. Ledergerber B. Battegay M. Grob P. Perrin L. Furrer H. et al. Clinical progression. survival. and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-1805.
33. Wood E. Hogg RS. Lima VD. Kerr T. Yip B. Marshall BD. Montaner JS. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300: 550-554.
34. McDonald SA. Hutchinson SJ. Bird SM. Mills PR. Dillon J. Bloor M. et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009; 18: 271-283.
35. Logtenberg-van der Grient H. Boland G. Mostert M. Schalm S. Onnodige sterfte door hepatitis B en C. Medisch Contact 2012; 8: 456-459.